About us

life molecular imaging

Your Partner for
Molecular Imaging

With the development of novel PET tracers for molecular imaging, Life Molecular Imaging (LMI) is focusing on a key area of modern medicine. LMI strives to be a leader in the field of molecular imaging by developing innovative products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life.

Life Molecular Imaging

Our Mission

We Provide Innovative PET Tracers
to Reduce the Burden of the Diseases

Our mission is to develop novel PET Tracers in the area of Molecular Imaging that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life.

life molecular imaging

Our History

Life Molecular Imaging (LMI) was founded in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG by Piramal and is now part of Life Healthcare’s Alliance Medical.

LMI offers an integrated business including research and development laboratories. We have partnered with radiopharmacies, imaging centres and universities around the world to provide global access to our products. LMI develops and commercialises radiopharmaceuticals used in molecular imaging and has a promising pipeline of products in development in neurogenerative and cardiovascular diseases. Our flagship product Neuraceq® is used to detect the accumulation of amyloid proteins in the brain, which is considered a major cause of Alzheimer’s disease. Neuraceq® is nowadays approved and produced in many countries around the globe.

Our purpose is to provide innovative molecular imaging solutions to reduce the burden of disease. This will make life better for patients. As we expand and grow our business into new markets, our goal will positively impact a greater number of people in more regions. Playing a role in improving patients’ lives is important and aligns with our purpose. It’s about making life better for everyone.

Key Milestones

Bayer spins out separate entity – Piramal Enterpises Ltd. becomes new owner

Neuraceq® approved by US & EU regulators

Acquired by Life Healthcare’s Alliance Medical

life molecular imaging

Part of the Life Healthcare International Group

An integrated business including research and development laboratories,
a network of cyclotrons, radiopharmacies and imaging facilities.

Emilia Clarke
Life Healthcare

Market-leading globally diversified healthcare provider with a large hospital and clinic network in South Africa.

Visit website
Emilia Clarke
Life Molecular Imaging

LMI develops and commercialises radiopharmaceuticals used in molecular imaging and has a promising pipeline of products in development across the neurogenerative and cardiovascular areas.
Emilia Clarke
Alliance Medical Limited

Europe's largest medical imaging company with an expanding network of radiopharmacies and PET CT and MR Imaging centres.

Visit website
Emilia Clarke
Life Radiopharma

Life Radiopharma f-con is your contact for the procurement and distribution of short-lived radiotracers for nuclear medicine diagnostics.

Visit website
Emilia Clarke
Alliance Medical GmbH

Alliance Medical Northern Europe has been one of the leading service providers in radiology and nuclear medicine for around 30 years.

Visit website
life molecular imaging

Our Partners

We are serving our customers with the help of the most experienced partners in the area of ​​Molecular Imaging.

life molecular imaging

Our Leadership Team

The members of Life Molecular Imaging’s leadership team have been working for 20+ years in the pharmaceutical industry.

Ludger Dinkelborg, PhD
Ludger Dinkelborg, PhD
Managing Director

Before joining Life Molecular Imaging, Dr. Dinkelborg served as Managing Director of Piramal Imaging GmbH, as Director of the Board of Piramal Imaging SA and was the Head of Diagnostic Imaging Research at Bayer HealthCare. He brings more than 30 years of R&D experience in the pharmaceutical industry.

He received his PhD in biology at Heinrich-Heine-University, Düsseldorf, Germany and stayed as guest researcher at the Max-Planck-Institute for Molecular Physiology in Dortmund. He became a fellow of the Konrad-Adenauer-Foundation, attended the Cranfield Schering University course for managers, and the Stanford Executive Program, at Stanford School of Business, Stanford, CA.

Andrew Stephens, MD, PhD
Andrew Stephens, MD, PhD
Chief Medical Officer

Dr. Stephens has more than 30 years of experience in the pharmaceutical industry, primarily in the areas of neurodegenerative diseases, oncology and diagnostic imaging. Previously, he was Chief Medical Officer at Piramal Imaging and the VP Head Experimental Medicine Oncology/Diagnostic Imaging for Bayer Pharma. He has held positions of increasing responsibility at NeXagen/NeXstar, Gilead, Schering AG, and OSI Pharmaceuticals.

He received his BA cum laude in chemistry from the University of Colorado, Boulder. He also received an MD with honors and a PhD in biochemistry, biophysics and genetics from the University of Colorado, Boulder. Dr. Stephens is Board certified in Internal Medicine and had a clinical practice before entering pharmaceutical development.

Nico Beukman
Nico Beukman
Chief Commercial Officer Europe, Middle East & Africa

Mr. Beukman has more than 25 years of experience in the medical industry with a proven track record for managing strategic growth and execution of sales, marketing and commercial activities. Throughout his career, he has implemented creative and effective solutions for driving revenue growth and improving profitability while managing multinational teams.

Prior to Life Molecular Imaging and Piramal Imaging, Mr. Beukman spent twelve years at Covidien now Curium, serving the company in various leadership roles. Mr. Beukman earned his National Diploma in Clinical Engineering at Tswane University of Technology in South Africa and more recently completed the Oxford Executive Leadership Program

Colleen Ruby, CNMT, RT(N)
Colleen Ruby, CNMT, RT(N)
Chief Operating Officer, Americas and APAC

Ms. Ruby joined the organization in 2014 as Piramal Imaging’s Head of National Sales in the US to identify the market, establish the company’s brand, and to build a salesforce for the launch of Neuraceq® (florbetaben F-18). Ms. Ruby is a Certified and Registered Nuclear Medicine Technologist with more than thirty years of healthcare experience. She holds a degree in Science in Nuclear Medicine Technology and continuously updates her skill set via continuing education courses in health and business applications. Prior to joining the company, Ms. Ruby served as IBA Molecular’s Vice President of Sales and Marketing where she cultivated a professional organization of high-level Sales and Marketing specialists in the Nuclear and Molecular disciplines of the healthcare industry. Ms. Ruby was also previously employed by The University of Pittsburgh Medical Center. She is an active member of the Society of Nuclear Medicine and Molecular Imaging and participates on behalf of the company in the Medical Imaging and Technology Alliance.

Mathias Berndt, PhD
Mathias Berndt, PhD
Head Chemical R&D & Manufacturing

At Life Molecular Imaging, Mathias is responsible for our global commercial manufacturing network as well as the technical development of our pipeline assets.

Mathias has more than 15 years year experience in the pharmaceutical industry and radiopharmaceutical development at all stages from discovery to development to New Drug Application and commercialization. Prior to his current role at Life Molecular Imaging, he was Head of Chemical R&D at Piramal Imaging and held R&D positions at Bayer Healthcare and Schering AG.

Mathias studied chemistry at the Technical University Dresden, received his PhD in organic chemistry from the Free University Berlin and worked as a researcher at the Research Center Rossendorf.

Nick Karabatsos
Nick Karabatsos
Chief Commercial Officer, Americas and APAC

Nick Karabatsos leads the US commercial organization for Life Molecular Imaging Ltd. In this role, Nick is responsible for all sales and marketing activities in the North America and supporting our Asia Pacific markets.

Nick has more than 20 years of experience in the healthcare industry. He has a proven track record of strong strategic growth, leading and building diverse teams, and commercial success.

Prior to joining Life Molecular Imaging, Nick spent 21 years at GE Healthcare serving the company in various leadership roles. Most recently, Nick was the Vice President and General Manager of the Molecular Imaging (MI) business for the US and Canada. He was responsible for all activities associated with the MI business and lead the team to double digit growth and market share. Nick has his BS degree from the United States Military Academy at West Point and served 5 years in the US Army.

Adrian Karasiewicz
Adrian Karasiewicz
Head of Finance

Adrian Karasiewicz is the Head of Finance at Life Molecular Imaging since May 2021, before served as Financial Controller since he joined the company in 2019. He brings more than 10 years of experience in corporate finance, serving before as an Accountant at Miranda Textiles and Financial Controller at Diehl Group.

He received his Master Degree in Finance and Accounting at Poznań University of Economics, Poland. He continues his development program at Association of Chartered Certified Accountants.

Michel Jongens
Michel Jongens
Chief Financial Officer - Molecular Imaging

Michel Jongens finished his bachelor’s in economics and joined the Dutch Wegener group in 1989 as finance manager. In 1994 he joined InteliCoat Technologies as finance director and he helped build this to be the European head office for this US subsidiary. In 2009 he joined Alliance Medical NE where he restructured the business and took on the role as MD in 2013, before coming CFO of AM NE and LMI in July 2018.

Donna Felker
Donna Felker
Head of Legal

Ms. Felker has been practicing law in the United States for 18 years, primarily in the life sciences and outsourced services industries. Prior to becoming a lawyer, Ms. Felker spent 14 years in positions of increasing responsibility in domestic (US) and global operations and client management.

Ms. Felker completed her Bachelor Degrees in Business Administration (Financial Management) and Human Resources at the University of Delaware, her Master of Science Degree in Business Administration at Boston University, and her Juris Doctorate at Creighton University School of Law.

life molecular imaging

Compliance & Code of Conduct

Life Molecular Imaging is committed to the highest standards of ethical, moral and legal business conduct. Ethical business behaviour is the responsibility of every person in the company and is reflected not only in our relationships with each other but also with our customers, suppliers, clients, contractors, shareholders, and other stakeholders.

Being true to our customers, our environment, and our company, and respecting each other are the fundamental expectations of every Life Molecular Imaging employee and our business partners.

Our culture of compliance, which is fully supported by our senior management, is supported with clear and consistent policies, compliance training, and open communication channels. Life Molecular Imaging has developed its Compliance Program to meet the specific needs of the company and continually assesses the effectiveness of its Compliance Program. We respond quickly to concerns and identify risks, administering corrective action when appropriate.

The Life Healthcare Code of Conduct and related corporate policies are a key component of our commitment to high standards of business and personal ethics.

As member of EFPIA (European Federation of Pharmaceutical Industries Association) Life Molecular Imaging is committed to comply with the EFPIA codes of standard as well as with applicable national laws and regulations for an open and transparent relationship with stakeholders across healthcare including healthcare professionals (HCPs), EU institutions and patient organizations.

Please click for our transparency reporting (as Life Molecular Imaging) for Calendar Year: 2020, 2021, 2022.

At Life Molecular Imaging we take violations against our Code of Conduct seriously: we thoroughly investigate known cases and take disciplinary actions where appropriate.

Ethics and Compliance Hotline:
Every Life Molecular Imaging representative (including company personnel and agents) has a duty to report any actual or suspected violations of any laws, regulations, government healthcare program requirements, internal policies and procedures, or inappropriate actions.

Employees, customers, business partners, and third parties may make report concerns either via calling one of the following toll-free call numbers:

  • USA: 1 866 317 7033
  • UK: 0808 189 5199
  • Germany: 08000 181 2227

or by sending an email to: Life@tip-offs.com

All reports submitted to the Integrity Line are handled by a third-party and treated with discretion. LMI does not tolerate any form of retaliation against individuals who report any suspected improper, unethical or illegal conduct.

We at LMI also engage with our various suppliers around the world to ensure they comply with the general principles of LMI’s Supplier Code of Conduct.

Neuraceq® - Product Indications And Use

PRODUCT INDICATIONS AND USE: Neuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A negative Neuraceq scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations.

Limitations: Limitations of Use
A positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder. The safety and effectiveness of Neuraceq have not been established for Predicting the development of dementia or other neurologic conditions or monitoring responses to therapies.



  • Risk for Image Misinterpretation and other Errors
    Errors may occur in the Neuraceq estimation of brain neuritic β-amyloid plaque density during image interpretation [see Clinical Studies (14)]. Image interpretation should be performed independently of the patient’s clinical information. The use of clinical information in the interpretation of Neuraceq images has not been evaluated and may lead to errors. Errors may also occur in cases with severe brain atrophy that limits the ability to distinguish gray and white matter on the Neuraceq scan. Errors may also occur due to motion artifacts that result in image distortion. Neuraceq scan results are indicative of the presence of brain neuritic β-amyloid plaques only at the time of image acquisition and a negative scan result does not preclude the development of brain neuritic β-amyloid plaques in the future.
  • Radiation Risk
    Neuraceq, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure [see Dosage and Administration.


  • The most commonly reported adverse reactions in clinical trials were injection site pain (3.4%), injection/appliucation site erythema (1.7%), injection site irritation (1.1%).


  • Drug-drug interaction studies have not been performed in patients to establish the extent, if any, to which concomitant medications may alter Neuraceq image results.


  • Pregnancy: All radiopharmaceuticals, including Neuraceq, have a potential to cause fetal harm depending on the stage of fetal development and the magnitude of the radiopharmaceutical dose. If considering Neuraceq administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from the drug and the gestational timing of exposure.
  • Lactation: There are no data on the presence of florbetaben F 18 injection in human milk, the effects on the breastfed infant, or the effects of florbetaben F 18 injection on milk production. Exposure of Neuraceq to a breastfed infant can be minimized by temporary discontinuation of breastfeeding. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Neuraceq and any potential adverse effects on the breastfed child from Neuraceq or from the underlying maternal condition.
  • Pediatric Use: Neuraceq is not indicated for use in pediatric patients.
  • Geriatric Use: No overall differences in safety were observed between older and younger subjects

A pharmacological overdose of Neuraceq is unlikely given the relatively low doses used for diagnostic purposes. In the event of administration of a radiation overdose with Neuraceq, the absorbed organ dose to the patient should be reduced by increasing elimination of the radionuclide from the body by inducing frequent micturition. Prior to Neuraceq administration, please read the full Prescribing Information for additional Important Safety Information.

SUSPECTED ADVERSE REACTIONS please report to: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program